Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Exciting advances in CAR-T therapy at the University of Colorado Cancer Center

Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, outlines some of the CAR-T constructs in development at the University of Colorado Cancer Center, including UCD19, an in-house manufactured CAR-T construct developed for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) (NCT04240808), and UCD19/22, a CAR-T therapy designed to treat patients with R/R aggressive B-cell lymphoma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Disclosures

Research Support/Funding: TG Therapeutics, Genentech, Novartis
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, Impact bio
Speaker’s bureau: SeaGen
DMC: Celgene , Genentech